Collaborative cancer epidemiology in the 21st century: The model of cancer consortia

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 12, 2013, Pages 2148-2160

  Burgio, Michael R ^a,c   Ioannidis, John P A ^d,e   Kaminski, Brett M ^a   DeRycke, Eric ^a   Rogers, Scott ^a   Khoury, Muin J ^a,b   Seminara, Daniela ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^c Scientific Consulting Group Inc   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER EPIDEMIOLOGY; CANCER MODEL; CANCER RESEARCH; FUNDING; FUTUROLOGY; GEOGRAPHIC DISTRIBUTION; HISTORY; HUMAN; INTERDISCIPLINARY RESEARCH; INTERNET; NATIONAL HEALTH ORGANIZATION; POLICY; PRIORITY JOURNAL; PRODUCTIVITY; PUBLIC-PRIVATE PARTNERSHIP; PUBLICATION; REVIEW; SCIENTIFIC LITERATURE; SOCIAL NETWORK; TEAMWORK; TRANSLATIONAL RESEARCH; WEB BROWSER;

EPIDEMIOLOGIC METHODS; HUMANS; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; UNITED STATES;

EID: 84890082143     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-13-0591     Document Type: Review

References (66)

1. Wuchty S, Jones BF, Uzzi B. The increasing dominance of teams in production of knowledge. Science 2007;316:1036-9.
2. Caporaso NE, Bennett SN. The rise of consortia. Nat Proc 2011. http://hdl.handle.net/10101/npre.2011.6680.1.
3. Boffetta P, Colditz GA, Potter JD, Kolonel L, Robson PJ, Malekzadeh R, et al. Cohorts and consortia conference: a summary report (Banff, Canada, June 17-19, 2009). Cancer Causes Control 2011; 22:463-8.
4. Vegvari A, Welinder C, Lindberg H, Fehniger TE, Marko-Varga G. Biobank resources for future patient care: developments, principles and concepts. J Clin Bioinforma 2011;1:24.
5. Hoover RN. The evolution of epidemiologic research: from cottage industry to "big" science. Epidemiology 2007;18:13-7.
6. NIH. EGRP-supported cancer epidemiology consortia. Bethesda, MD: NIH [cited 2013 May 2]. Available from: http://epi.grants.cancer.gov/Consortia/.
7. NIH. Breast cancer and the environment research centers. Bethesda, MD: NIH; 2002 [cited 2013 Apr 30]. Available from: http://grants.nih.gov/grants/ guide/rfa-files/RFA-ES-03-001.html.
8. NIH. Cooperative family registry for epidemiologic studies of breast cancer. Bethesda, MD: NIH; 1994 [cited 2013 Apr 30]. Available from: http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-95-003.html.
9. NIH. Cooperative family registry for epidemiologic studies of colon cancer. Bethesda, MD: NIH; 1996 [cited 2013 Apr 30]. Available from: http://grants.nih.gov/grants/guide/notice-files/not96-192.html.
10. NIH. NIH sharing policies and related guidance on NIH-funded research resources. Bethesda, MD: NIH 2013 [cited 2013 May 16]; Available from: http://grants.nih.gov/grants/sharing.htm.
11. NIH. NIH RePORTER: research project success rates by type and activity. Bethesda, MD: NIH. [cited May 6, 2013]; Available from: http://report.nih.gov/ success-rates/Success-ByActivity.cfm.
12. Hall KL, Feng AX, Moser RP, Stokols D, Taylor BK. Moving the science of team science forward: collaboration and creativity. Am J Prev Med 2008;35(2 Suppl):S243-9.
13. PubMed. Bethesda, MD: U.S. National Library of Medicine [cited 2013 Apr 30]. Available from: http://www.ncbi.nlm.nih.gov/pubmed.
14. Austin MA, Hair MS, Fullerton SM. Research guidelines in the Era of large-scale collaborations: an analysis of genome-wide association study consortia. Am J Epidemiol 2012;175:962-9.
15. Thun MJ, Hoover RN, Hunter DJ. Bigger, better, sooner-scaling up for success. Cancer Epidemiol Biomarkers Prev 2012;21:571-5.
16. Hindorff LA, Sethupathy P, Junkins HA, Ramos EM, Mehta JP, Collins FS, et al. Potential etiologic and functional implications of genomewide association loci for human diseases and traits. Proc Natl Acad Sci U S A 2009;106:9362-7.
17. A catalog of published genome-wide association studies. [database on the Internet; cited 2013 Jan 24]. Available from: www.genome.gov/gwastudies.
18. Disis ML, Slattery JT. The road we must take: multidisciplinary team science. Sci Transl Med 2010;2:22cm9.
19. Rebbeck TR, Paskett E, Sellers TA. Fostering transdisciplinary science. Cancer Epidemiol Biomarkers Prev 2010;19:1149-50.
20. Facilitating interdisciplinary research. The National Academies Press; 2004.
21. Khoury MJ, Coates RJ, Evans JP. Evidence-based classification of recommendations on use of genomic tests in clinical practice: dealing with insufficient evidence. Genet Med 2010; 12:680-3.
22. Khoury MJ, Gwinn M, Yoon PW. The continuum of translation research in genomic medicine: how can we accelerate the appropriate integration of human genome discoveries into health care and disease prevention. Genet Med 2007;9:665-74.
23. Schully SD, Benedicto CB, Gillanders EM, Wang SS, Khoury MJ. Translational research in cancer genetics: the road less traveled. Public Health Genomics 2011;14:1-8.
24. Schully SD, Benedicto CB, Khoury MJ. How can we stimulate translational research in cancer genomics beyond bench to bedside? Genet Med 2012;14:169-70.
25. Freedman ND, Murray LJ, Kamangar F, Abnet CC, Cook MB, Nyren O, et al. Alcohol intake and risk of oesophageal adenocarcinoma: a pooled analysis from the BEACON Consortium. Gut 2011;60:1029-37.
26. Fabbri M, Bottoni A, Shimizu M, Spizzo R, Nicoloso MS, Rossi S, et al. Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA 2011; 305:59-67.
27. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen SL, Godwin AK, et al. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res 2001;61:5420-4.
28. Kastrinos F, Steyerberg EW, Mercado R, Balmana J, Holter S, Gallinger S, et al. The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history. Gastroenterology 2011;140:73-81.
29. Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010;304: 967-75.
30. Kefford RF, Newton Bishop JA, Bergman W, Tucker MA. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: a consensus statement of the Melanoma Genetics Consortium. J Clin Oncol 1999;17:3245-51.
31. Wirtzfeld DA, Mikula L, Gryfe R, Ravani P, Dicks EL, Parfrey P, et al. Concordance with clinical practice guidelines for adjuvant chemotherapy in patients with stage I-III colon cancer: experience in 2 Canadian provinces. Can J Surg 2009;52:92-7.
32. Watkins KE, Way CY, Fiander JJ, Meadus RJ, Esplen MJ, Green JS, et al. Lynch syndrome: barriers to and facilitators of screening and disease management. Hered Cancer Clin Pract 2011;9:8.
33. Ramsey SD, Clarke L, Etzioni R, Higashi M, Berry K, Urban N. Costeffectiveness of microsatellite instability screening as a method for detecting hereditary nonpolyposis colorectal cancer. Ann Intern Med 2001;135:577-88.
34. Newcomb PA, Storer BE, Morimoto LM, Templeton A, Potter JD. Longterm efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003;95:622-5.
35. John EM, Hopper JL, Beck JC, Knight JA, Neuhausen SL, Senie RT, et al. The Breast Cancer Family Registry: an infrastructure for cooperative multinational, interdisciplinary and translational studies of the genetic epidemiology of breast cancer. Breast Cancer Res 2004;6: R375-89.
36. Newcomb PA, Baron J, Cotterchio M, Gallinger S, Grove J, Haile R, et al. Colon Cancer Family Registry: an international resource for studies of the genetic epidemiology of colon cancer. Cancer Epidemiol Biomarkers Prev 2007;16:2331-43.
37. Knoppers BM, Harris JR, Tasse AM, Budin-Ljosne I, Kaye J, Deschenes M, et al. Towards a data sharing Code of Conduct for international genomic research. Genome Med 2011;3:46.
38. Verma M, Khoury MJ, Ioannidis JP. Opportunities and challenges for selected emerging technologies in cancer epidemiology: mitochondrial, epigenomic, metabolomic, and telomerase profiling. Cancer Epidemiol Biomarkers Prev 2013;22:189-200.
39. Lam TK, Spitz M, Schully SD, Khoury MJ. "Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev 2013;22:181-8.
40. Onar A, Ramamurthy U, Wallace D, Boyett JM. An operational perspective of challenging statistical dogma while establishing a modern, secure distributed data management and imaging transport system: the Pediatric Brain Tumor Consortium phase I experience. Clin Transl Sci 2009;2:143-9.
41. Poussaint TY, Phillips PC, Vajapeyam S, Fahey FH, Robertson RL, Osganian S, et al. The Neuroimaging Center of the Pediatric Brain Tumor Consortium-collaborative neuroimaging in pediatric brain tumor research: a work in progress. AJNR Am J Neuroradiol 2007; 28:603-7.
42. Cai Q, Long J, Lu W, Qu S, Wen W, Kang D, et al. Genome-wide association study identifies breast cancer risk variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet 2011; 20:4991-9.
43. Chenevix-Trench G, Milne RL, Antoniou AC, Couch FJ, Easton DF, Goldgar DE. An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). Breast Cancer Res 2007;9:104.
44. Neuhausen SL, Ozcelik H, Southey MC, John EM, Godwin AK, Chung W, et al. BRCA1 and BRCA2 mutation carriers in the Breast Cancer Family Registry: an open resource for collaborative research. Breast Cancer Res Treat 2009;116:379-86.
45. Spurdle AB, Healey S, Devereau A, Hogervorst FB, Monteiro AN, Nathanson KL, et al. ENIGMA-evidence-based network for the interpretation of germline mutant alleles: an international initiative to evaluate risk and clinical significance associated with sequence variation in BRCA1 and BRCA2 genes. Hum Mutat 2012; 33:2-7.
46. Hunter DJ, Riboli E, Haiman CA, Albanes D, Altshuler D, Chanock SJ, et al. A candidate gene approach to searching for low-penetrance breast and prostate cancer genes. Nat Rev Cancer 2005;5: 977-85.
47. Jia WH, Zhang B, Matsuo K, Shin A, Xiang YB, Jee SH, et al. Genome-wide association analyses in East Asians identify new susceptibility loci for colorectal cancer. Nat Genet 2013;45: 191-6.
48. Olson SH, Chen C, De Vivo I, Doherty JA, Hartmuller V, Horn-Ross PL, et al. Maximizing resources to study an uncommon cancer: E2C2-Epidemiology of Endometrial Cancer Consortium. Cancer Causes Control 2009;20:491-6.
49. Conway DI, Hashibe M, Boffetta P, Wunsch-Filho V, Muscat J, La Vecchia C, et al. Enhancing epidemiologic research on head and neck cancer: INHANCE - The international head and neck cancer epidemiology consortium. Oral Oncol 2009;45:743-6.
50. Boffetta P, Armstrong B, Linet M, Kasten C, Cozen W, Hartge P. Consortia in cancer epidemiology: lessons from InterLymph. Cancer Epidemiol Biomarkers Prev 2007;16:197-9.
51. Kricker A, Armstrong BK, Goumas C, Kanetsky P, Gallagher RP, Begg CB, et al. MC1R genotype may modify the effect of sun exposure on melanoma risk in the GEM study. Cancer Causes Control 2010;21: 2137-47.
52. Ragin CC, Taioli E, McFarlane-Anderson N, Avery G, Bennett F, Bovell-Benjamin A, et al. African-Caribbean cancer consortium for the study of viral, genetic and environmental cancer risk factors. Infect Agent Cancer 2007;2:17.
53. Rolland B, Smith BR, Potter JD. Coordinating centers in cancer epidemiology research: the Asia Cohort Consortium coordinating center. Cancer Epidemiol Biomarkers Prev 2011;20:2115-9.
54. Song M, Rolland B, Potter JD, Kang D. Asia Cohort Consortium: challenges for collaborative research. J Epidemiol 2012;22:287-90.
55. Anton-Culver H, Ziogas A, Bowen D, Finkelstein D, Griffin C, Hanson J, et al. The Cancer Genetics Network: recruitment results and pilot studies. Community Genet 2003;6:171-7.
56. Brown RC, Dwyer T, Kasten C, Krotoski D, Li Z, Linet MS, et al. Cohort profile: the International Childhood Cancer Cohort Consortium (I4C). Int J Epidemiol 2007;36:724-30.
57. West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, et al. Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 2010;76:1295-6.
58. Olsen CM, Nagle CM, Whiteman DC, Ness R, Pearce CL, Pike MC, et al. Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocr Relat Cancer 2013; 20:251-62.
59. Petersen GM, de Andrade M, Goggins M, Hruban RH, Bondy M, Korczak JF, et al. Pancreatic cancer genetic epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2006;15:704-10.
60. Doherty R, Lubinski J, Manguoglu E, Luleci G, Christie M, Craven P, et al. AIDIT and IMPACT: building research collaborations in targeted prostate cancer screening. J BUON 2006;11:415-8.
61. Mitra AV, Bancroft EK, Barbachano Y, Page EC, Foster CS, Jameson C, et al. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study. BJU Int 2011;107:28-39.
62. Mitra AV, Bancroft EK, Eeles RA. A review of targeted screening for prostate cancer: introducing the IMPACT study. BJU Int 2007;99: 1350-5.
63. Schaid DJ, Chang BL. Description of the International Consortium For Prostate Cancer Genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13. Prostate 2005;63:276-90.
64. Xu J, Lange EM, Lu L, Zheng SL, Wang Z, Thibodeau SN, et al. HOXB13 is a susceptibility gene for prostate cancer: results from the International Consortium for Prostate Cancer Genetics (ICPCG). Hum Genet 2013;132:5-14.
65. Rebbeck TR, Devesa SS, Chang BL, Bunker CH, Cheng I, Cooney K, et al. Global patterns of prostate cancer incidence, aggressiveness, and mortality in men of African descent. Prostate Cancer 2013;2013: 560857.
66. Kote-Jarai Z, Olama AA, Giles GG, Severi G, Schleutker J, Weischer M, et al. Seven prostate cancer susceptibility loci identified by a multistage genome-wide association study. Nat Genet 2011;43:785-91.